Argenica Therapeutics Limited (ASX:AGN)
Share Pricing & News Healthcare

AUD 0.52

-0.01 (1.887%)
(As on 2022-12-06 20:55:09 AEDT)
Previous Close Open Close*
0.53 0.53 0.52
Market Cap Dividend Yield (Annualized)
AUD 45.2M 0.00%

Day Range
0.52L 0.53 H
52 WEEK HIGH LOW
0.35L 0.9 H

Chart Price & Information

Last Trade 0.52
Change% -1.8868
52 W H/L 0.900/0.350
EBITDA -4.09M
NPAT After Abnormal Items -4.091M
Equity 8.307M
ROE% -49.24%
Total Liabilities 735,909
Total Revenue 259,098
Cash and Cash Equivalents 8.914M

Stock Information

Share price 0.52
Market Cap 45.2M
Price/Gross Cash Flow -13.05
Dividend Yield Excluding Special 0.00%
Ending Shares 86.922M
52-Week Range 0.900-0.350
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.10
P/E ratio 0.000
Sector P/E --
EPS -5.50
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.04
Net Gearing -107.31%
Sales Per Share 0.00
Book Value Per Share 0.10

Similar Companies

Related Articles

About Company

Argenica Therapeutics Limited (AGN) operated in development and commercialisation of a novel drug developed by world-leading researchers at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute). Argenica's current business is to develop a best in class neuroprotective drug based on the pioneering work of Assoc.

Corporate Information


Suite 2, 29 The Avenue, NEDLANDS, WA, AUSTRALIA, 6009

Phone:+61 8 9329 3396

Email:info@argenica.com.au

Website:https://argenica.com.au/

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2023-08-22 2023
Report (Prelim) 2023-08-22 2023
Report (Interim) 2023-02-21 2023